Navigation Links
NuVasive to Present at the JMP Securities Healthcare Focus Conference
Date:9/29/2009

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Chief Financial Officer and Executive Vice President, is scheduled to present at the JMP Securities Healthcare Focus Conference at The New York Palace Hotel in New York, New York, on Tuesday, October 6, 2009, at 12:00 noon ET.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery wit
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
2. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
3. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
4. ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented
5. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
6. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
7. QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
8. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
10. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
11. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... the 150 million customer mark, an intense debate continues ... once led by nonprofits. "Microfinance Meets the Market," just ... advances the debate, presenting new research from Jonathan Morduch ... University,s Wagner Graduate School of Public Service, and Robert ...
... better balance in a slippery situation , , FRIDAY, Feb. ... where the footing is unstable helped train them to ... says a University of Illinois at Chicago study. ... develops fall prevention strategies that can be used in ...
... Ill., Feb. 20 Abbott ( NYSE: ABT ) ... from the European Commission for its acquisition of Advanced ... the outstanding shares of common stock of AMO. ... the condition to the tender offer related to European ...
... CHADDS FORD, Pa. and DANBURY, Conn., Feb. 20 ... Pharmaceuticals (Nasdaq: PPCO ) announced today that ... LLC regarding the production and sale of generic formulations ... Endo and Penwest have agreed to dismiss their ...
... FOR RELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, ... Bride, (651) 695-2795, jmacbride@aan.com , Young Smokers Increase ... start smoking before age 17 may increase their risk ... released today that will be presented at the American ...
... Treatment targeting damaged brain areas did not bring significant ... (HealthDay News) -- An experimental laser treatment of ... stroke patients, researchers report. , The trial was the ... stroke. , In the trial, the researchers at the ...
Cached Medicine News:Health News:Research reveals best paths for success as microfinance sector grows 2Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Laser Therapy Disappoints in Stroke Trial 2
Clearview H. pylori II uses rapid, two-step technology for the direct detection of H. pylori antibodies. , ,The patented, innovative technology used by Clearview H. pylori II provides highly sen...
... FlexSure HP is a visually read, ... antibodies to H. pylori, a bacterium that ... with peptic ulcer disease and some gastric ... either whole blood or serum samples, provides ...
... Acceava Mononucleosis test provides superior performance ... a simple procedure that provides an ... with competitive products will convince you ... enable you to deliver improved patient ...
... A rapid test for ... heterophile antibodies specific to infectious ... or whole blood specimens. This ... aid in the diagnosis of ...
Medicine Products: